Developer docs
API playgroundTry for free, no card

Search company profiles

Mission Bio

Full company profile

uuid00008nf

Namestring
Mission Bio
Legal namestring
Mission Bio, Inc.
Websiteurl
missionbio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Mission Bio, Inc. is a privately held Delaware-incorporated life-sciences-tools company headquartered in South San Francisco, California, founded in 2012 with 101–250 employees. The company develops and commercializes the Tapestri Platform, which is described as the first and only single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform uses targeted amplicon-based panels and droplet-based single-cell isolation, and is sold alongside dedicated assay modules (DNA+Protein, DNA+CpG Methylation, SNV+CNV, DNA+RNA, Single-Cell Genome Integrity, and Single-Cell VCN Assay for CAR-T), as well as supporting software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer) accessed via an AWS-hosted client portal.

Mission Bio serves two primary customer segments: biopharmaceutical companies (drug developers and clinical sponsors using Tapestri for biomarker discovery, trial stratification, and mechanism-of-action studies in oncology, hematologic malignancies, and cell and gene therapy) and academic medical centers and research universities (independent investigators conducting hematology, oncology, and cell-therapy research, with a particularly strong footprint in AML/MRD, multiple myeloma, myeloproliferative neoplasms, and CRISPR-editing characterization). Notable enterprise and academic relationships include Incyte (INCA033989 MPN program, ASH 2025), Heidelberg University Hospital and the BLAST trial consortium, the University of Miami (multiple myeloma), the Human Cell Atlas consortium, and Integrated DNA Technologies (paired rhAmpSeq/Tapestri CRISPR workflow). Key collaborators and clinical co-development sites also include City of Hope, Children's Hospital Colorado, University of Colorado Anschutz, Weill Cornell Medicine, and the New York Genome Center.

The business model combines instrument sales, recurring consumables (reagents, cartridges, kits, panels), enterprise software access, and professional services (Pharma Assay Development for Cell & Gene Therapy and Drug Development). Pricing is quote-based under multi-year enterprise contracts; products are research-use-only and the company holds ISO Certification and operates AWS-hosted infrastructure with HIPAA/GDPR-aligned data practices. The company has raised approximately $150M+ in disclosed equity across Series B (2017–2018), Series C ($70M, 2020, led by Novo Holdings), a 2022 $40M round, and an August 2025 Ally Bridge Group-led round with participation from Agilent, Cota Capital, Mayfield Fund, and Novo Holdings. Recent strategic emphasis is on biopharma clinical adoption, cell-and-gene-therapy QC, and global academic footprint, supported by a leadership team that added a new CMO (Zivjena Vucetic, October 2025) and a new CCO (Matthew Cato, August 2025).

Short descriptiontext

Mission Bio develops the Tapestri single-cell multi-omics platform, the only technology co-measuring DNA, RNA, protein, and CpG methylation from the same cells, serving biopharmaceutical companies and academic medical centers in oncology, hematologic malignancies, cell and gene therapy, and CRISPR-editing research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell multiomics, single-cell DNA sequencing, cancer biomarker discovery, cell therapy characterization, clonal evolution analysis
Industry2 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Testing Laboratories and Services541380
SIC code2 codes
  • Services-Testing Laboratories8734
  • Laboratory Analytical Instruments3826
Product category
Single-Cell Multi-omics Instruments and Consumables
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument sales (Tapestri hardware)
TypeHardware Sales
Description

Sells Tapestri instruments and onboard instrument software under Terms and Conditions of Sale; warranty covers devices for one year from pickup date.

missionbio.com
2Reagents, consumables, kits, cartridges, panels
TypeSubscription Recurring
Description

Sells reagents, cartridges, and panels (consumables) on FOB basis with warranty through expiration date. Recurring revenue tied to instrument installed base and ongoing research usage.

missionbio.com
3Pharma Assay Development (PAD) services
TypeProfessional Services
Description

Custom assay design and bioinformatics services for biopharma and cell/gene therapy developers (PAD for Cell & Gene Therapy and PAD for Drug Development).

missionbio.com
4Software / bioinformatics access (Tapestri Insights, Pipeline, Designer, Portal)
TypeSubscription Recurring
Description

Provides Tapestri Insights, Tapestri Pipeline, Tapestri Designer, and a web-based portal for client data processing and analysis hosted on AWS.

missionbio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Quote-based enterprise pricing for Tapestri Platform, panels, reagents, and PAD services
ModelOtherBilling cadenceMulti-year contract
Notes

No public price list; customers must request a quote. Instrument sales include one-year device warranty; reagent warranty extends through expiration date. RUO-only products.

missionbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Tapestri Platform
Description

Mission Bio's flagship single-cell multi-omics platform offering end-to-end workflow from sample preparation to visualization with DNA, RNA, protein, and CpG methylation readouts.

missionbio.com
Core offering1 text field

Mission Bio develops and sells the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform combines a proprietary instrument, targeted Panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV), the Tapestri Insights/Pipeline/Designer bioinformatics software suite, and custom Pharma Assay Development (PAD) services for cell and gene therapy and oncology drug development customers. Mission Bio also offers the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay for advanced therapy safety characterization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Single-cell transduction assay achieved 99.2% to 99.9% sensitivity and 98.8% to 99.6% specificity in CAR-T vector copy number measurement
+4 more records
Product overview1 text field

Mission Bio operates a single unified platform-plus-modules architecture centered on the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV/CNV), RNA, protein, and CpG methylation from the same cells. The core platform is augmented by (a) targeted Panels (SNV, SNV+CNV, DNA+Protein, DNA+CpG Methylation, DNA+RNA), (b) software components Tapestri Insights, Tapestri Pipeline, and Tapestri Designer for analysis, design, and visualization, (c) the Pharma Assay Development (PAD) service with sub-offerings PAD for Cell & Gene Therapy and PAD for Drug Development, and (d) dedicated assay modules such as the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay. Together these pieces form an end-to-end workflow from sample preparation through publication-ready multi-omic insights used globally for oncology research, hematologic malignancies, cell and gene therapy development, and precision medicine biomarker discovery.

Product and service8 records
1Tapestri Platform
CategoryCore instrument platform
Description

End-to-end single-cell multiomics workflow from sample preparation to visualization with publication-ready insights. The first and only single-cell technology developed to reveal biomarkers that stratify patients, signal resistance, and predict relapse by connecting genotype and phenotype at single-cell resolution. Sells Tapestri instruments, onboard instrument software, reagents, cartridges, panels, and bioinformatics software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer).

2Panels
CategoryConsumables / targeted panels
Description

Targeted consumable panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV) that focus on key regions of interest for efficient use of sequencing budget and analysis time on the Tapestri Platform. Sold on FOB basis with warranty through expiration date; recurring revenue tied to instrument installed base.

3Pharma Assay Development (PAD)
CategoryProfessional services
Description

Custom assay development service for pharmaceutical and biopharma customers, including custom panel design, assay optimization, and complex single-cell data analysis with bioinformatics support to support clinical development and biomarker discovery.

4PAD for Cell & Gene Therapy
CategoryProfessional services
Description

Specialized pharma assay development service for cell and gene therapy programs, including custom VCN amplicon panel design, on/off-target editing analysis, and genome integrity assessment for advanced therapy developers.

5PAD for Drug Development
CategoryProfessional services
Description

Pharma assay development service tailored for drug development workflows, supporting biomarker discovery, mechanism-of-action studies, and patient stratification in oncology and hematology programs.

6Tapestri Single-Cell Genome Integrity Solution
CategoryStandalone product / assay
Description

Single-cell solution that measures whole-genome copy number variation at single-cell resolution in advanced therapies and tumor samples, addressing safety assessment for cell and gene therapy manufacturing.

7scG2P Single-Cell Profiling Technique
CategoryResearch technique / productized method
Description

Single-cell profiling technique co-developed with Weill Cornell Medicine and the New York Genome Center that maps pre-malignant gene mutations in solid tissues; published in Cancer Discovery.

8Tapestri Single-Cell Sequencing Service
CategoryProfessional services
Description

Service-based access to the Tapestri Platform offered to research customers (e.g., through Avancebio and academic core facilities) for outsourced single-cell multi-omics experiments.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Collaboration giving HCA members discounted access to Mission Bio's Tapestri Platform for single-cell multiomics analysis. Includes access to validated assays, bioinformatics support, and custom assay development capabilities for research across genomics, transcriptomics, proteomics, and related omics fields. Announced ahead of the HCA General Meeting 2026 (June 16–18, Boston).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Scientific coordination of the randomized phase II BLAST clinical trial in AML; retrospective Tapestri analysis identified CXCR4 as a predictive biomarker for Motixafortide in AML (results published in Blood, 2026).

3Martin Luther University Halle-Wittenberg
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Sponsor of the investigator-initiated BLAST phase II clinical trial in AML (128 patients across 29 academic centers in Germany); Tapestri was used for retrospective single-cell analysis of bone marrow samples.

missionbio.com
4East German Study Group for Hematology and Oncology (OSHO)
Strategic tierMinorTypeOthersAnnounced on2026-06-03
Description

Active supporter of the BLAST phase II AML trial; Mission Bio conducted retrospective single-cell analysis on trial samples using Tapestri.

missionbio.com
5Study Alliance Leukemia (SAL)
Strategic tierMinorTypeOthersAnnounced on2026-06-03
Description

Active supporter of the BLAST phase II AML trial with Mission Bio Tapestri retrospective analysis.

missionbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Collaboration on the Molecular Therapy Advances publication using Tapestri to profile vector copy number (VCN), surface protein expression, and vector integrity across ~10,000 individual CAR-T cells in a single assay.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances, demonstrating 99.2%–99.9% sensitivity and 98.8%–99.6% specificity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-15
Description

Co-developed the scG2P single-cell profiling technique that maps pre-malignant gene mutations in solid tissues, published in Cancer Discovery. Found that more than half of over 10,000 sampled esophageal cells contained clonal driver mutations, with NOTCH1 most common.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-15
Description

Collaboration with Mission Bio and Weill Cornell Medicine to develop the scG2P single-cell profiling technique for pre-malignant mutations in solid tissues.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Tapestri Platform supported exploratory biomarker analysis for Incyte's INCA033989 clinical trial for myeloproliferative neoplasms (MPNs), with data presented at ASH 2025. Single-cell DNA and protein profiling enabled Incyte to better characterize clonal diversity, track resistance mechanisms, and refine patient stratification strategies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-21
Description

Research collaboration using paired rhAmpSeq + Tapestri workflow for multi-scale characterization of CRISPR editing outcomes in primary human T cells (targeting PDCD1, TCRA, TCRB); published as a Mission Bio technical note.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-06
Description

Partnership to advance single-cell precision in CRISPR genome editing analysis. Pairs IDT's rhAmpSeq bulk population-level assay with Mission Bio's Tapestri single-cell multiomics for two-tier CRISPR editing characterization (99.77%–99.93% indel detection, novel translocations in as few as 1 in 25,000 cells).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-02
Description

Partnership with top researchers from the University of Miami to accelerate early relapse detection and treatment selection of multiple myeloma patients using the Tapestri Platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Akoya's CODEX and Phenoptics spatial biology platforms compete for the same immuno-oncology and translational research budgets as Tapestri. While Akoya focuses on spatial proteomics rather than genotype-phenotype co-measurement, both are positioning around single-cell-level biomarker discovery.

TypeDirect peer
Description

Standard BioTools historically pioneered single-cell targeted DNA/multi-omics workflows (Hyperion, CyTOF, Advanta) and directly competes with Tapestri in targeted single-cell genomics and immuno-oncology profiling. Both serve translational research and biopharma customers with single-cell assays.

TypeEmerging player
Description

Cytek's spectral flow cytometry platforms (Aurora, Northern Lights) compete for immunology and immuno-oncology research dollars alongside Mission Bio's DNA+Protein assay. Both enable high-dimensional single-cell phenotyping in translational and clinical research settings.

TypeRegional player
Description

Element's AVITI sequencing platform enables lower-cost sequencing that complements or substitutes for upstream single-cell library prep platforms. As a next-gen sequencing platform vendor, Element is an ecosystem peer for customers evaluating end-to-end single-cell multi-omics workflows.

TypeBroad incumbent
Description

BD's Rhapsody single-cell analysis platform competes with Tapestri in targeted and whole-transcriptome single-cell sequencing, particularly in immunology and oncology research. BD offers broader flow cytometry and reagent portfolios versus Mission Bio's focused multi-omics platform.

TypeEmerging player
Description

Parse offers scalable single-cell RNA sequencing (Evercode) without instrument requirements, targeting the same translational and academic customer base as Mission Bio. It represents an emerging competitive alternative for hypothesis-generation use cases that today are adjacent to Tapestri's targeted panels.

TypeBroad incumbent
Description

Bio-Rad's ddPCR and Droplet Digital PCR products are the gold-standard bulk alternative to Tapestri for cell therapy QC (e.g., vector copy number). Bio-Rad represents both a competitive incumbent in CAR-T characterization and a logical strategic acquirer of Mission Bio's single-cell multi-omics platform.

TypeEmerging player
Description

Singular's G4 sequencing platform serves the same translational and clinical research sequencing market that underpins Tapestri's workflow. While not a direct single-cell competitor, Singular represents an alternative sequencing backbone for customers building single-cell pipelines.

TypeBroad incumbent
Description

NanoString's nCounter and GeoMx platforms compete for oncology translational research spend alongside Tapestri. Both serve biopharma biomarker discovery workflows, though NanoString emphasizes spatial and bulk molecular profiling rather than single-cell multi-omics.

TypeBroad incumbent
Description

10x Genomics is the dominant single-cell sequencing platform (Chromium) with a much larger installed base and whole-transcriptome focus. It is the primary competitive threat to Mission Bio's Tapestri, increasingly extending into targeted multi-omics and cell-therapy characterization applications.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mission Bio

Single-Cell Multi-omics Instruments and Consumablesmissionbio.com

Mission Bio develops the Tapestri single-cell multi-omics platform, the only technology co-measuring DNA, RNA, protein, and CpG methylation from the same cells, serving biopharmaceutical companies and academic medical centers in oncology, hematologic malignancies, cell and gene therapy, and CRISPR-editing research.

What Mission Bio does

Mission Bio, Inc. is a privately held Delaware-incorporated life-sciences-tools company headquartered in South San Francisco, California, founded in 2012 with 101–250 employees. The company develops and commercializes the Tapestri Platform, which is described as the first and only single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform uses targeted amplicon-based panels and droplet-based single-cell isolation, and is sold alongside dedicated assay modules (DNA+Protein, DNA+CpG Methylation, SNV+CNV, DNA+RNA, Single-Cell Genome Integrity, and Single-Cell VCN Assay for CAR-T), as well as supporting software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer) accessed via an AWS-hosted client portal.

Mission Bio serves two primary customer segments: biopharmaceutical companies (drug developers and clinical sponsors using Tapestri for biomarker discovery, trial stratification, and mechanism-of-action studies in oncology, hematologic malignancies, and cell and gene therapy) and academic medical centers and research universities (independent investigators conducting hematology, oncology, and cell-therapy research, with a particularly strong footprint in AML/MRD, multiple myeloma, myeloproliferative neoplasms, and CRISPR-editing characterization). Notable enterprise and academic relationships include Incyte (INCA033989 MPN program, ASH 2025), Heidelberg University Hospital and the BLAST trial consortium, the University of Miami (multiple myeloma), the Human Cell Atlas consortium, and Integrated DNA Technologies (paired rhAmpSeq/Tapestri CRISPR workflow). Key collaborators and clinical co-development sites also include City of Hope, Children's Hospital Colorado, University of Colorado Anschutz, Weill Cornell Medicine, and the New York Genome Center.

The business model combines instrument sales, recurring consumables (reagents, cartridges, kits, panels), enterprise software access, and professional services (Pharma Assay Development for Cell & Gene Therapy and Drug Development). Pricing is quote-based under multi-year enterprise contracts; products are research-use-only and the company holds ISO Certification and operates AWS-hosted infrastructure with HIPAA/GDPR-aligned data practices. The company has raised approximately $150M+ in disclosed equity across Series B (2017–2018), Series C ($70M, 2020, led by Novo Holdings), a 2022 $40M round, and an August 2025 Ally Bridge Group-led round with participation from Agilent, Cota Capital, Mayfield Fund, and Novo Holdings. Recent strategic emphasis is on biopharma clinical adoption, cell-and-gene-therapy QC, and global academic footprint, supported by a leadership team that added a new CMO (Zivjena Vucetic, October 2025) and a new CCO (Matthew Cato, August 2025).

Mission Bio firmographics

Firmographics
Name
Mission Bio
Legal name
Mission Bio, Inc.
Website
https://missionbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Mission Bio develops the Tapestri single-cell multi-omics platform, the only technology co-measuring DNA, RNA, protein, and CpG methylation from the same cells, serving biopharmaceutical companies and academic medical centers in oncology, hematologic malignancies, cell and gene therapy, and CRISPR-editing research.
Ownership category
akta.pro rank

Mission Bio industry classification

Industry
Product category
Single-Cell Multi-omics Instruments and Consumables
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380)
SIC
Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Single-cell multiomics
  • Single-cell DNA sequencing
  • Cancer biomarker discovery
  • Cell therapy characterization
  • Clonal evolution analysis

Where Mission Bio is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Mission Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Instrument sales (Tapestri hardware): Sells Tapestri instruments and onboard instrument software under Terms and Conditions of Sale; warranty covers devices for one year from pickup date.
  2. Reagents, consumables, kits, cartridges, panels: Sells reagents, cartridges, and panels (consumables) on FOB basis with warranty through expiration date. Recurring revenue tied to instrument installed base and ongoing research usage.
  3. Pharma Assay Development (PAD) services: Custom assay design and bioinformatics services for biopharma and cell/gene therapy developers (PAD for Cell & Gene Therapy and PAD for Drug Development).
  4. Software / bioinformatics access (Tapestri Insights, Pipeline, Designer, Portal): Provides Tapestri Insights, Tapestri Pipeline, Tapestri Designer, and a web-based portal for client data processing and analysis hosted on AWS.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing for Tapestri Platform, panels, reagents, and PAD services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Mission Bio product offering

Product offering

Core offering

Mission Bio develops and sells the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform combines a proprietary instrument, targeted Panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV), the Tapestri Insights/Pipeline/Designer bioinformatics software suite, and custom Pharma Assay Development (PAD) services for cell and gene therapy and oncology drug development customers. Mission Bio also offers the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay for advanced therapy safety characterization.

Product overview

Mission Bio operates a single unified platform-plus-modules architecture centered on the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV/CNV), RNA, protein, and CpG methylation from the same cells. The core platform is augmented by (a) targeted Panels (SNV, SNV+CNV, DNA+Protein, DNA+CpG Methylation, DNA+RNA), (b) software components Tapestri Insights, Tapestri Pipeline, and Tapestri Designer for analysis, design, and visualization, (c) the Pharma Assay Development (PAD) service with sub-offerings PAD for Cell & Gene Therapy and PAD for Drug Development, and (d) dedicated assay modules such as the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay. Together these pieces form an end-to-end workflow from sample preparation through publication-ready multi-omic insights used globally for oncology research, hematologic malignancies, cell and gene therapy development, and precision medicine biomarker discovery.

Differentiator

Problem solved

Functional benefit

Brands

  • Tapestri Platform: Mission Bio's flagship single-cell multi-omics platform offering end-to-end workflow from sample preparation to visualization with DNA, RNA, protein, and CpG methylation readouts.

Products and services

  • Tapestri Platform End-to-end single-cell multiomics workflow from sample preparation to visualization with publication-ready insights. The first and only single-cell technology developed to reveal biomarkers that stratify patients, signal resistance, and predict relapse by connecting genotype and phenotype at single-cell resolution. Sells Tapestri instruments, onboard instrument software, reagents, cartridges, panels, and bioinformatics software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer).
  • Panels Targeted consumable panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV) that focus on key regions of interest for efficient use of sequencing budget and analysis time on the Tapestri Platform. Sold on FOB basis with warranty through expiration date; recurring revenue tied to instrument installed base.
  • Pharma Assay Development (PAD) Custom assay development service for pharmaceutical and biopharma customers, including custom panel design, assay optimization, and complex single-cell data analysis with bioinformatics support to support clinical development and biomarker discovery.
  • PAD for Cell & Gene Therapy Specialized pharma assay development service for cell and gene therapy programs, including custom VCN amplicon panel design, on/off-target editing analysis, and genome integrity assessment for advanced therapy developers.
  • PAD for Drug Development Pharma assay development service tailored for drug development workflows, supporting biomarker discovery, mechanism-of-action studies, and patient stratification in oncology and hematology programs.
  • Tapestri Single-Cell Genome Integrity Solution Single-cell solution that measures whole-genome copy number variation at single-cell resolution in advanced therapies and tumor samples, addressing safety assessment for cell and gene therapy manufacturing.
  • scG2P Single-Cell Profiling Technique Single-cell profiling technique co-developed with Weill Cornell Medicine and the New York Genome Center that maps pre-malignant gene mutations in solid tissues; published in Cancer Discovery.
  • Tapestri Single-Cell Sequencing Service Service-based access to the Tapestri Platform offered to research customers (e.g., through Avancebio and academic core facilities) for outsourced single-cell multi-omics experiments.

Quantifiable outcome

  • Single-cell transduction assay achieved 99.2% to 99.9% sensitivity and 98.8% to 99.6% specificity in CAR-T vector copy number measurement
  • +4 more outcomes

Companies that use Mission Bio

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles3 records

Mission Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature9 records

Mission Bio partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

  • Human Cell Atlas (HCA)flagshipStrategic or Co-development Partner · 9 June 2026Collaboration giving HCA members discounted access to Mission Bio's Tapestri Platform for single-cell multiomics analysis. Includes access to validated assays, bioinformatics support, and custom assay development capabilities for research across genomics, transcriptomics, proteomics, and related omics fields. Announced ahead of the HCA General Meeting 2026 (June 16–18, Boston).
  • Heidelberg University HospitalcoreStrategic or Co-development Partner · 3 June 2026Scientific coordination of the randomized phase II BLAST clinical trial in AML; retrospective Tapestri analysis identified CXCR4 as a predictive biomarker for Motixafortide in AML (results published in Blood, 2026).
  • Martin Luther University Halle-WittenbergcoreStrategic or Co-development Partner · 3 June 2026Sponsor of the investigator-initiated BLAST phase II clinical trial in AML (128 patients across 29 academic centers in Germany); Tapestri was used for retrospective single-cell analysis of bone marrow samples.
  • East German Study Group for Hematology and Oncology (OSHO)minorOthers · 3 June 2026Active supporter of the BLAST phase II AML trial; Mission Bio conducted retrospective single-cell analysis on trial samples using Tapestri.
  • Study Alliance Leukemia (SAL)minorOthers · 3 June 2026Active supporter of the BLAST phase II AML trial with Mission Bio Tapestri retrospective analysis.
  • City of HopecoreStrategic or Co-development Partner · 30 April 2026Collaboration on the Molecular Therapy Advances publication using Tapestri to profile vector copy number (VCN), surface protein expression, and vector integrity across ~10,000 individual CAR-T cells in a single assay.
  • Children's Hospital ColoradocoreStrategic or Co-development Partner · 30 April 2026Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances, demonstrating 99.2%–99.9% sensitivity and 98.8%–99.6% specificity.
  • University of Colorado AnschutzcoreStrategic or Co-development Partner · 30 April 2026Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances.
  • Weill Cornell MedicinecoreStrategic or Co-development Partner · 15 January 2026Co-developed the scG2P single-cell profiling technique that maps pre-malignant gene mutations in solid tissues, published in Cancer Discovery. Found that more than half of over 10,000 sampled esophageal cells contained clonal driver mutations, with NOTCH1 most common.
  • New York Genome CentercoreStrategic or Co-development Partner · 15 January 2026Collaboration with Mission Bio and Weill Cornell Medicine to develop the scG2P single-cell profiling technique for pre-malignant mutations in solid tissues.
  • IncyteflagshipStrategic or Co-development Partner · 4 December 2025Tapestri Platform supported exploratory biomarker analysis for Incyte's INCA033989 clinical trial for myeloproliferative neoplasms (MPNs), with data presented at ASH 2025. Single-cell DNA and protein profiling enabled Incyte to better characterize clonal diversity, track resistance mechanisms, and refine patient stratification strategies.
  • Bar-Ilan University (Hendel lab)coreStrategic or Co-development Partner · 21 May 2025Research collaboration using paired rhAmpSeq + Tapestri workflow for multi-scale characterization of CRISPR editing outcomes in primary human T cells (targeting PDCD1, TCRA, TCRB); published as a Mission Bio technical note.
  • Integrated DNA Technologies (IDT)coreStrategic or Co-development Partner · 6 May 2025Partnership to advance single-cell precision in CRISPR genome editing analysis. Pairs IDT's rhAmpSeq bulk population-level assay with Mission Bio's Tapestri single-cell multiomics for two-tier CRISPR editing characterization (99.77%–99.93% indel detection, novel translocations in as few as 1 in 25,000 cells).
  • University of MiamicoreStrategic or Co-development Partner · 2 December 2024Partnership with top researchers from the University of Miami to accelerate early relapse detection and treatment selection of multiple myeloma patients using the Tapestri Platform.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Mission Bio competitors and assessment

Company assessment

Emerging players

  • Akoya Biosciences: Akoya's CODEX and Phenoptics spatial biology platforms compete for the same immuno-oncology and translational research budgets as Tapestri. While Akoya focuses on spatial proteomics rather than genotype-phenotype co-measurement, both are positioning around single-cell-level biomarker discovery.
  • Cytek Biosciences: Cytek's spectral flow cytometry platforms (Aurora, Northern Lights) compete for immunology and immuno-oncology research dollars alongside Mission Bio's DNA+Protein assay. Both enable high-dimensional single-cell phenotyping in translational and clinical research settings.
  • Parse Biosciences: Parse offers scalable single-cell RNA sequencing (Evercode) without instrument requirements, targeting the same translational and academic customer base as Mission Bio. It represents an emerging competitive alternative for hypothesis-generation use cases that today are adjacent to Tapestri's targeted panels.
  • Singular Genomics: Singular's G4 sequencing platform serves the same translational and clinical research sequencing market that underpins Tapestri's workflow. While not a direct single-cell competitor, Singular represents an alternative sequencing backbone for customers building single-cell pipelines.

Direct peers

  • Standard BioTools (formerly Fluidigm): Standard BioTools historically pioneered single-cell targeted DNA/multi-omics workflows (Hyperion, CyTOF, Advanta) and directly competes with Tapestri in targeted single-cell genomics and immuno-oncology profiling. Both serve translational research and biopharma customers with single-cell assays.

Regional players

  • Element Biosciences: Element's AVITI sequencing platform enables lower-cost sequencing that complements or substitutes for upstream single-cell library prep platforms. As a next-gen sequencing platform vendor, Element is an ecosystem peer for customers evaluating end-to-end single-cell multi-omics workflows.

Broad incumbents

  • BD Biosciences (BD Rhapsody): BD's Rhapsody single-cell analysis platform competes with Tapestri in targeted and whole-transcriptome single-cell sequencing, particularly in immunology and oncology research. BD offers broader flow cytometry and reagent portfolios versus Mission Bio's focused multi-omics platform.
  • Bio-Rad Laboratories: Bio-Rad's ddPCR and Droplet Digital PCR products are the gold-standard bulk alternative to Tapestri for cell therapy QC (e.g., vector copy number). Bio-Rad represents both a competitive incumbent in CAR-T characterization and a logical strategic acquirer of Mission Bio's single-cell multi-omics platform.
  • NanoString Technologies (Bruker Spatial Biology): NanoString's nCounter and GeoMx platforms compete for oncology translational research spend alongside Tapestri. Both serve biopharma biomarker discovery workflows, though NanoString emphasizes spatial and bulk molecular profiling rather than single-cell multi-omics.
  • 10x Genomics: 10x Genomics is the dominant single-cell sequencing platform (Chromium) with a much larger installed base and whole-transcriptome focus. It is the primary competitive threat to Mission Bio's Tapestri, increasingly extending into targeted multi-omics and cell-therapy characterization applications.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Mission Bio social profiles

Digital presence

Mission Bio compliance and trust

Trust signal

Compliance5 records

Mission Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mission Bio leadership team

Management profile

Number of profiles

Profiles5 records

Mission Bio funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mission Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mission Bio

What does Mission Bio do?

Mission Bio develops and sells the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform combines a proprietary instrument, targeted Panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV), the Tapestri Insights/Pipeline/Designer bioinformatics software suite, and custom Pharma Assay Development (PAD) services for cell and gene therapy and oncology drug development customers. Mission Bio also offers the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay for advanced therapy safety characterization.

Is Mission Bio a public or private company?

Mission Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mission Bio founded?

Mission Bio was founded in 2014. It employs 51 to 100 people.

Where is Mission Bio based?

Mission Bio is headquartered in South San Francisco, United States, in the North America region.

How does Mission Bio make money?

Four revenue lines are on record. Instrument sales (Tapestri hardware) is the primary driver. The others are reagents, consumables, kits, cartridges, panels, pharma Assay Development (PAD) services and software / bioinformatics access (Tapestri Insights, Pipeline, Designer, Portal).

Who are Mission Bio's main competitors?

Emerging players on record are Akoya Biosciences, Cytek Biosciences, Parse Biosciences and Singular Genomics. Standard BioTools (formerly Fluidigm) is listed as a direct peer. Element Biosciences is listed as a regional player. Broad incumbents are BD Biosciences (BD Rhapsody), Bio-Rad Laboratories, NanoString Technologies (Bruker Spatial Biology) and 10x Genomics.

Does Mission Bio have an API?

No public API is recorded for Mission Bio.

What industry is Mission Bio in?

Mission Bio's product category is Single-Cell Multi-omics Instruments and Consumables. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq). Its NAICS code is 541714 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx SummitMission Bio announced that Merck, Incyte, and itself will present single-cell multiomics data at the World CDx Summit. Merck will show CRISPR-edited variant effects, Incyte will present data on its calreticulin-targeted therapy, and Mission Bio will report single-cell MRD sensitivity of 93% versus 43% for flow cytometry in AML.BioSpaceMission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx SummitMission Bio announced that Merck, Incyte, and itself will present single-cell multiomics data at the World CDx Summit. Merck will show CRISPR-edited variant effects, Incyte will present data on its calreticulin-targeted therapy, and Mission Bio will report single-cell MRD sensitivity of 93% versus 43% for flow cytometry in AML.Business Wire BlogMission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx SummitMission Bio announced that Merck, Incyte, and itself will present new data using its Tapestri platform at the World CDx Summit. Merck and Incyte will share single-cell multiomics findings, while Mission Bio will present clinical data showing single-cell MRD profiling achieved 93% sensitivity versus 43% for flow cytometry in AML.Business Wire BlogMission Bio Launches Tapestri® Triomics for Simultaneous DNA, RNA, and Protein Analysis at Single-Cell ResolutionMission Bio announced Tapestri Triomics, a platform that simultaneously analyzes DNA, RNA, and protein in the same cell. The technology connects genotype, gene expression, and phenotype at single-cell resolution, with early work in hematologic disease. It is available for research use only and will be showcased at ASHG 2026.ClinicbarcelonaLa plataforma de genómica amplía sus servicios de single cell con la incorporación de la tecnolThe Functional Genomics Core Facility added Mission Bio's Tapestri single-cell technology, funded by the Spanish Ministry of Science's FORTALECE programme. The system detects genetic variants and protein markers at single-cell level, enabling studies of cellular heterogeneity in cancer, haematology, immunology, and personalised medicine.The Medicine MakerSingle-Cell Analysis Reveals Hidden CAR T Manufacturing RisksMission Bio used its Tapestri single-cell multiomic platform to measure vector copy number and surface protein expression in individual CAR T cells, revealing high-copy outliers that bulk methods miss. Cells with VCN >5 carry elevated genotoxicity risk, and single-cell analysis enables safer product release. The company expects single-cell assays to become validated lot-release tests in GxP environments.Business Wire BlogMission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 MeetingMission Bio announced a collaboration with the Human Cell Atlas (HCA), giving HCA members discounted access to Mission Bio's Tapestri® Platform for single-cell multiomics analysis. The partnership includes access to validated assays, bioinformatics support, and custom assay development capabilities to support research across genomics, transcriptomics, proteomics, and related omics fields. The announcement was made ahead of the HCA General Meeting 2026, scheduled for June 16–18 in Boston.BioSpaceMission Bio’s Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST TrialMission Bio and Heidelberg University Hospital reported a retrospective single-cell analysis of the BLAST trial in AML, finding high CXCR4 expression on residual leukemic cells predicts reduced relapse risk with Motixafortide. The signal was invisible to standard-of-care methods, and the findings are hypothesis-generating, requiring prospective confirmation.Business Wire BlogMission Bio De-risks CRISPR-Engineered T Cells Through Single-Cell Analysis of Genomic Edits and Gene ExpressionMission Bio released data showing its Tapestri assay resolves CRISPR edit co-occurrence, allelic zygosity, and gene expression in individual T cells. The assay deconvoluted clonal heterogeneity in three Jurkat lines, revealing a dose-dependent relationship between editing zygosity and pathway expression. The findings will be presented at ASGCT in Boston.